Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues1.5b1.8b2.1b2.5b2.8b3.2b3.6b
% growth70 %18 %18 %20 %13 %14 %12 %
EBITDA(465m)(740m)(480m)(13.1m)348m517m695m
% EBITDA margin(31 %)(42 %)(23 %)(1 %)12 %16 %19 %
Profit(849m)(596m)(624m)(204m)(165m)(11.9m)148m
% profit margin(57 %)(34 %)(30 %)(8 %)(6 %)-4 %
EV / revenue13.8x8.2x5.0x6.0x4.6x4.0x3.4x
EV / EBITDA-44.3x-19.7x-21.7x-1135.8x37.7x24.7x17.5x
R&D budget554m386m393m426m---
R&D % of revenue37 %22 %19 %17 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$8.2m

Early VC
*
N/A

$600m

Post IPO Debt
*
N/A

$850m

Post IPO Debt
*
N/A

$500m

Post IPO Convertible
*

$204k

Post IPO Equity
*
N/A

$621m

Post IPO Convertible
Total Funding€7.5m

Recent News about Exact Sciences

Edit
More about Exact Sciencesinfo icon
Edit

Exact Sciences is a biotechnology company focused on the early detection and prevention of cancer. Headquartered in Madison, Wisconsin, the company operates globally, providing advanced diagnostic tests that help detect cancer at its earliest stages and guide treatment decisions. Exact Sciences serves healthcare providers, patients, and research institutions, operating in the medical diagnostics market. The company's business model revolves around the development, manufacturing, and sale of cancer screening and diagnostic tests, generating revenue primarily through test sales and partnerships with healthcare organizations. Exact Sciences aims to reduce the burden of cancer through innovative solutions and comprehensive support for patients and healthcare professionals.

Keywords: cancer diagnostics, early detection, biotechnology, healthcare, medical diagnostics, cancer screening, treatment guidance, global operations, healthcare providers, innovative solutions.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Armune BioScience
ACQUISITION by Exact Sciences Feb 2018
Genomic Health
ACQUISITION by Exact Sciences Jul 2019
Paradigm Diagnostics
ACQUISITION by Exact Sciences Mar 2020
Biomatrica
ACQUISITION by Exact Sciences Oct 2018
Sampleminded
ACQUISITION by Exact Sciences Aug 2017
View 43 more